Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

548
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
548
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

780
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
780
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

897
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
897
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

1.1K
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
1.1K
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

703
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
703
Rheumatic Heart Disease IV: Nursing Management01:20

Rheumatic Heart Disease IV: Nursing Management

489
AssessmentA comprehensive assessment is essential in managing a patient with rheumatic heart disease (RHD). Begin with obtaining a detailed medical history, including recent streptococcal infections, a history of rheumatic fever, or previously diagnosed rheumatic heart disease. Assess the patient for symptoms such as fever, chest pain, widespread joint pain (arthralgia), tachycardia, pericardial friction rub, muffled heart sounds, heart murmurs, peripheral edema, subcutaneous nodules, and...
489

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Targeting Obesity in Psoriatic Arthritis: Is It Time for a Paradigm Change?

Arthritis & rheumatology (Hoboken, N.J.)·2026
Same author

To the homeRNAmax: Developing an Improved Blood Self-Collection and Stabilization Platform for Remote Transcriptomic Studies.

Analytical chemistry·2026
Same author

Beyond Pain Intensity: The Relationship Between Pain Catastrophizing and Quality of Life in Psoriatic Arthritis.

The Journal of rheumatology·2026
Same author

Artificial intelligence versus experts: Navigating challenging cases in psoriatic disease.

The Journal of investigative dermatology·2026
Same author

Multi-cohort Analysis Reveals Microbiome Signatures Associated with Drug Response in New-Onset Rheumatoid Arthritis.

bioRxiv : the preprint server for biology·2026
Same author

Glucagon-Like Peptide-1 Receptor Agonist Therapy Is Associated With Improvement in Psoriatic Arthritis-Related and Metabolic Outcomes: A Retrospective Analysis of Two Cohorts.

Arthritis & rheumatology (Hoboken, N.J.)·2026

Related Experiment Video

Updated: May 6, 2026

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
04:50

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain

Published on: May 16, 2025

1.5K

Monotherapy in rheumatoid arthritis.

Jose U Scher

    Bulletin of the Hospital for Joint Disease (2013)
    |October 25, 2013
    PubMed
    Summary

    Biologic disease-modifying anti-rheumatic drugs (DMARDs) offer new rheumatoid arthritis (RA) treatment options. This review explores evidence for biologic monotherapy in RA, particularly for patients intolerant to traditional synthetic DMARDs.

    Area of Science:

    • Rheumatology
    • Immunology
    • Pharmacology

    Background:

    • Rheumatoid arthritis (RA) treatment has evolved from anti-inflammatories to disease-modifying anti-rheumatic drugs (DMARDs).
    • Methotrexate (MTX) and biologic agents, like anti-TNFα inhibitors, represent significant advancements in altering RA's natural history.
    • Current guidelines often recommend combination therapy (e.g., MTX plus a biologic) for severe RA.

    Purpose of the Study:

    • To review the evidence supporting the use of biologic DMARDs in rheumatoid arthritis.
    • To identify specific patient populations and circumstances where biologic monotherapy may be indicated.
    • To discuss the potential of biologic monotherapy as an alternative to combination therapy.

    Main Methods:

    • Literature review of available evidence on biologic DMARDs in RA.

    More Related Videos

    An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
    07:37

    An Adoptive Transfer Model of Rheumatoid Arthritis in Mice

    Published on: June 6, 2025

    1.5K

    Related Experiment Videos

    Last Updated: May 6, 2026

    Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
    04:50

    Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain

    Published on: May 16, 2025

    1.5K
    An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
    07:37

    An Adoptive Transfer Model of Rheumatoid Arthritis in Mice

    Published on: June 6, 2025

    1.5K
  • Analysis of studies investigating biologic monotherapy versus combination therapy.
  • Examination of patient profiles with synthetic DMARD intolerance or side effects.

    • Main Results:

    • Biologic DMARDs have demonstrated efficacy in altering RA progression.
    • Evidence suggests potential for biologic monotherapy in select RA cases.
    • Patient intolerance or side effects to synthetic DMARDs may necessitate alternative strategies.

    Conclusions:

    • Biologic DMARDs are valuable therapeutic options for rheumatoid arthritis.
    • Biologic monotherapy presents a viable alternative for certain RA patients, especially those with contraindications to synthetic DMARDs.
    • Further research into optimal biologic monotherapy regimens is warranted.